Program

Program Tuesday, 7 November 2017

7:00 - 18:00
REGISTRATION HELP DESK HOURS (Hall 5)
Room: Hall 5
7:30 - 8:30
EDUCATIONAL SYMPOSIUM
7:30 - 8:30
Room: Lomond Auditorium (Loch Suite)
CHANGING THE HEALTH TECHNOLOGY ASSESSMENT PARADIGM FOR COMBINATION THERAPIES

(Sponsored by Takeda Pharmaceuticals International AG)

7:45 - 8:45
ISPOR BIOSIMILAR SPECIAL INTEREST GROUP OPEN MEETING
Room: Boisdale (Loch Suite)

All ISPOR members interested in or working with Biosimilar are welcome to attend an open meeting to discuss the formation of an ISPOR Biosimilar Special Interest Group meeting. This meeting will provide an opportunity for participants to learn about the formation and structure of Special Interest Groups (SIGs) at ISPOR and discuss the formation of a new SIG to explore the issues within the Biosimilar space identifying projects to address them.

8:00 - 18:00
SPEAKER READY ROOM HOURS (Fyne-Loch Suite)
Room: Fyne (Loch Suite)
8:30 - 19:15
EXHIBIT/POSTER HALL HOURS (Hall 4)
Room: Hall 4
8:45 - 9:45
BREAKOUT SESSION

8:45 - 9:45
Room: Lomond Auditorium (Loch Suite)

IP9: SHOULD RARE ONCOLOGY TREATMENTS BE CONSIDERED TRUE ORPHANS?

Moderator:

Annabel Griffiths, PhD, Consultant - Rare Diseases Lead, Costello Medical Consulting Ltd, Cambridge, UK

Panelists:

Elangovan Gajraj, MSc, Senior Technical Adviser, Scientific Advice, National Institute for Health and Care Excellence, London, UK

Pan Pantziarka, PhD, Project Co-ordinator, Anti-Cancer Fund, Strombeek-Bever, Belgium

Ivana Cattaneo, MBA, Public Affairs Director, Novartis Oncology Europe, Novartis Farma S.p.A, Origgio (VA), Italy


8:45 - 9:45
Room: Hall 2

IP10: DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?

Moderator:

Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

Panelists:

Karl Claxton, PhD, Professor of Economics, Centre for Health Economics and Department of Economics, University of York, York, UK

Ross Maclean, MD, SVP, Head of Medical, Precision Health Economics, Los Angeles, CA, USA

Jens Grueger, PhD, Head Global Pricing & Market Access, F. Hoffmann-LaRoche, Division Pharma, Basel, Switzerland


8:45 - 9:45
Room: Forth (Armadillo)
W9: PATIENTS´ PREFERENCES IN THE EUROPEAN REGULATORY ENVIRONMENT: A CRITICAL REVIEW
Discussion Leaders:

Axel C. Mühlbacher, PhD, MBA, Professor, Health Economics and Health Care Management, Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany

Kevin Marsh, PhD, Executive Director, Outcomes Research, Evidera Ltd, London, UK

Janine A. van Til, PhD, Assistant Professor Preference Research, Health Technology and Services Research, MIRA institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands


8:45 - 9:45
Room: Hall 3
W10: EQ-5D: IS NICE READY FOR THE NEXT LEVEL?
Discussion Leaders:

Rosemary Lovett, PhD, Senior Scientific Adviser, Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE), London, UK

Allan Wailoo, MA, MSc, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield, Sheffield, UK

Nancy Devlin, PhD, Director of Research, Office of Health Economics, London, UK


8:45 - 9:45
Room: Hall 1
P9: MEDICAL DEVICE & DIAGNOSTICS STUDIES
Moderator: Katarzyna Kolasa, PhD
Principal Senior Consultant Market Access, Straub Medical, Wangs, Switzerland

MD1

8:45 - 9:00

DO WE KNOW ENOUGH YET? A CUMULATIVE COST-EFFECTIVENESS ANALYSIS OF MECHANICAL THROMBECTOMY

Teljeur C1, Ryan M2, Glynn R3, Harrington P4
1Health Information and Quality Authority, Dublin, Ireland, 2Health Information and Quality Authority (HIQA), Dublin, Ireland, 3Health Service Executive, Dublin, Ireland, 4Health Information and Quality Authority, Dublin 7, Ireland

MD2

9:00 - 9:15

SOUTH WEST ICERS – THE EXPERIENCE OF NICE’S DIAGNOSTICS ASSESSMENT PROGRAMME

Nixon F, Walker T, Maloney J, Albrow R
National Institute for Health and Care Excellence, Manchester, UK

MD3

9:15 - 9:30

COST-EFFECTIVENESS OF DIAGNOSIS: FROM TESTS TO LONG-TERM OUTCOMES AND COSTS

Faria R1, Soares M2, Spackman E3, Ahmed H4, Brown L5, Kaplan RS5, Emberton M6, Sculpher M2
1University of York, Heslington, York, UK, 2University of York, York, UK, 3University of Calgary, Calgary, AB, Canada, 4Imperial College Healthcare NHS Trust, London, UK, 5MRC Clinical Trials Unit at UCL, London, UK, 6University College Hospitals NHS Foundation Trust, London, UK

MD4

9:30 - 9:45

EVALUATING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON TECHNIQUES: IMPACT ON HEALTH-RELATED QUALITY OF LIFE OF FOCUSSED ULTRASOUND THALAMOTOMY AND OTHER INTERVENTIONS FOR THE TREATMENT OF MEDICATION-REFRACTORY ESSENTIAL TREMOR

Langford BE1, Ridley CJ1, Beale RC2, Marsh W1, Caseby SC1, Richard L3
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Consulting Ltd, London, UK, 3InSightec Ltd, Tirat Carmel, Israel

8:45 - 9:45
Room: Gala (Armadillo)
P10: METHODS IN PATIENT PREFERENCE STUDIES
Moderator: Matthijs Versteegh, PhD
Business Director, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands

PP1

8:45 - 9:00

MIMICKING REAL LIFE DECISION-MAKING IN HEALTH: ALLOWING RESPONDENTS TIME-TO-THINK IN A DISCRETE CHOICE EXPERIMENT

Veldwijk J1, Viberg Johansson J2, Donkers B1, de Bekker-Grob E1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Uppsala University, Uppsala, Sweden

PP2

9:00 - 9:15

CHOICE OF INSTRUMENT IMPACTS HEALTHCARE DECISIONS: EFFECT OF SOURCE OF UTILITY DERIVED FROM THE SAME PATIENT POPULATION ON COST-EFFECTIVENESS

Gunsoy NB1, Cockle SM2, Doyle S2, Asukai Y1
1GSK, Uxbridge, UK, 2GSK, Brentford, Middlesex, UK

PP3

9:15 - 9:30

THE COMPARATIVE PERFORMANCE OF THE CHU-9D AND ADQOL AMONGST CHILDREN AGED 5 YEARS OR MORE WITH ECZEMA: EVIDENCE FROM THE CLOTHES RANDOMISED CONTROLLED TRIAL

Sach TH1, McManus E1, Thomas K2, Montgomery A2, Harrison E2, Williams H2, on behalf of the CLOTHES trial team -2
1University of East Anglia, Norwich, UK, 2University of Nottingham, Nottingham, UK

PP4

9:30 - 9:45

DOES USING FACTOR ANALYSIS TO SELECT COVARIATES IN MAPPING ALGORITHMS IMPROVE PREDICTIVE ACCURACY? A CASE OF MAPPING THE CORE 23-ITEM WOMEN’S HEALTH QUESTIONNAIRE ONTO THE EQ-5D-5L AND SF-6D

Kaambwa B1, de Lacey S1, Smith C2, Ratcliffe J3
1Flinders University, Adelaide, Australia, 2Western Sydney University, Sydney, Australia, 3University of South Australia, Adelaide, Australia
8:45 - 13:30
RESEARCH POSTER PRESENTATIONS - SESSION III
9:45 - 10:15
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III (Hall 4)
Room: Hall 4
10:15 - 12:00
WELCOME & SECOND PLENARY SESSION
Room: Clyde Auditorium (Armadillo)
WELCOME FROM ISPOR PRESIDENT
Speaker: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Room: Clyde Auditorium (Armadillo)
WELCOME FROM ISPOR CHIEF SCIENCE OFFICER
Speaker: Richard J. Willke, PhD
Chief Science Officer, ISPOR, Lawrenceville, NJ, USA
Room: Clyde Auditorium (Armadillo)
2017 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
AWARDEE: Claire Rothery, PhD bio
Senior Research Fellow. Centre for Health Economics, University of York, Heslington, York, UK
Room: Clyde Auditorium (Armadillo)
2017 VALUE IN HEALTH REGIONAL ISSUES (CEEWAA) EXCELLENT ARTICLE AWARD
AWARDEE: Ales Tichopad, PhD bio
Kantar Health s.r.o., Prague, Czech Republic
Room: Clyde Auditorium (Armadillo)
SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?
Health technology assessment (HTA) processes vary across jurisdictions.  Some countries are early adopters and include a formal economic evaluation (Canada, United Kingdom, Australia, Sweden, The Netherlands), others have a less arduous approach without formal QALY-type assessment (France, Spain, Italy), and still others prefer to reference HTAs performed elsewhere (Romania, Bulgaria).  In addition, bodies such as EUnetHTA offer the potential to streamline processes by enabling information sharing and structured collaboration between jurisdictions.  However, how cost-effective are the HTA processes? What is the value for money of the HTA activities? Is there a “perfect HTA process” that can serve as the benchmark for other countries to adopt or adapt?  This plenary session will explore how HTA processes (or lack of HTA processes) might be compared and evaluated.  The speakers will present different perspectives on evaluating the value of HTA processes and a discussant will provide an economist’s view.
Moderator: Andrew Briggs, DPhil bio
William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK
Speaker: Susan Guthrie, PhD, MSci bio
Research Leader, Rand Europe, Cambridge, UK
Speaker: Nicola Allen, PhD bio
Senior Consultant, Global Pricing and Product Strategy, Precision Xtract, London, UK
Speaker: Zoe Garrett, MPhil, MRes bio
Senior Technical Adviser, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), & Lead, JA3 Work Package 7, EUnetHTA, Manchester, UK
12:00 - 14:00
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III (Hall 4)
Room: Hall 4
12:30 - 13:30
ISPOR MEDICAL DEVICES AND DIAGNOSTICS SPECIAL INTEREST GROUP OPEN MEETING
Room: Lomond Auditorium (Loch Suite)
The ISPOR Medical Devices and Diagnostics Special Interest Group will hold an open meeting to update members on: medical technology projects ISPOR is participating; present the new structure of ISPOR Special Interest Groups (SIGs); identify new projects and discuss leadership opportunities in the SIG. Open to all ISPOR members. 
12:30 - 13:30
ISPOR PATIENT CENTERED SPECIAL INTEREST GROUP OPEN MEETING
Room: Hall 1
Join the ISPOR Patient Centered Special Interest Group for a discussion on their findings from a systematic review conducted on definitions for patient engagement, patient centeredness, and related terms.  Attendees interested in this topic are encouraged to provide input and feedback on key results from a qualitative content analysis of over 150 unique definitions identified in the systematic review. The audience will also hear comments and reactions from patient representatives who have been actively involved in the research.
12:30 - 13:30
EDUCATIONAL SYMPOSIUM
12:30 - 13:30
Room: Clyde Auditorium (Armadillo)
PRACTICAL IMPLICATIONS OF VALUE-BASED PRICING AND EMERGING VALUE FRAMEWORKS IN HEALTH TECHNOLOGY ASSESSMENT

(Sponsored by Xcenda)

12:30 - 13:30
POSTER AUTHOR DISCUSSION HOUR - SESSION III (Hall 4)
Room: Hall 4
12:30 - 14:00
ISPOR WOMEN IN HEOR/SCIENCE OPEN MEETING
Room: Boisdale (Loch Suite)
ISPOR is exploring the foundation of a “Women in HEOR/Science” initiative to help support the growth, development, and contribution of women in health economics and outcomes research (HEOR) and to serve as a catalyst for women’s leadership in the field. The objective of this session is to share the vision for the initiative and to gain feedback from members to help guide its development. The session will be led by ISPOR President (2017-2018) Shelby D. Reed, PhD, RPh, Professor, Duke University, Durham, NC, USA and Olivia Wu, PhD, Professor and Director, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.
14:00 - 15:00
BREAKOUT SESSION

14:00 - 15:00
Room: Hall 2

IP11: DETERMINING VALUE IN HEALTH TECHNOLOGY ASSESSMENT CONSISTENT WITH SOCIETAL AIMS: PURSUE NEW OPTIONS?

Moderator:

J. Jaime Caro, MDCM, FRCPC, FACP, Chief Scientist, Evidera, Waltham, MA, USA and Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada

Panelists:

Alistair McGuire, BA, MLitt, PhD, Professor, Health Economics at the LSE Health and Social Care, Social Policy, London School of Economics and Political Science, London, UK

John Brazier, PhD, MSc, Professor of Health Economics and Dean, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Michael Schlander, MD, PhD, MBA, Professor of Health Economics at the University of Heidelberg, Head of the Division of Health Economics at the German Cancer Research Center, and Foundation Chairman & Scientific Director, Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany


14:00 - 15:00
Room: Hall 3

IP12: WHAT SHOULD PATIENT-CENTERED CARE MEAN IN THE WELFARE STATES OF EUROPE? THE UNITED KINGDOM AND GERMANY CANNOT BOTH BE RIGHT

Moderator:

F. Reed Johnson, PhD, Professor, Duke Clinical Research Institute, Durham, NC, USA

Panelists:

Axel C. Mühlbacher, PhD, MBA, Professor, Health Economics and Health Care Management, Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany

Nancy Devlin, PhD, Research Director, Office of Health Economics, London, UK


14:00 - 15:00
Room: Clyde Auditorium (Armadillo)
W11: DETERMINING THE VALUE OF LONG TERM OUTCOMES ASSOCIATED WITH IMMUNO-ONCOLOGY THERAPIES - CHALLENGES AND APPROACHES FOR OS EXTRAPOLATIONS
Discussion Leaders:

Yiduo Zhang, PhD, Director, Health Economics and Payer Analytics, Global Payer Evidence and Pricing, AstraZeneca, Gaithersburg, MD, USA

Pralay Mukhopadhyay, PhD, Statistician, Astrazeneca, Gaithersburg, MD, USA

Andrew Briggs, DPhil, Visiting Investigator, Center for Health Policy and Outcomes, Department of Epidemiology & Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Nicholas Latimer, MSc, PhD, Senior Research Fellow, ScHARR, University of Sheffield, Sheffield, UK

Min Huang, Ph.D., Principal Scientist, Predictive & Economic Modeling, Center for Observational and Real-world Evidence, Merck & Co., Inc., North Wales, PA, USA


14:00 - 15:00
Room: Forth (Armadillo)
W12: GETTING TO THE HEART OF THE MATTER: REAL-WORLD EVIDENCE AS AN INDISPENSABLE SOURCE FOR THE ONGOING ASSESSMENT OF CARDIOVASCULAR TREATMENTS
Discussion Leaders:

Kathleen E. Hughes, MBA, Vice President, Avalere Health LLC, Washington, DC, USA

Colin Berry, FRCP, PhD, Professor, University of Glasgow, Glasgow, UK

Pall Jonsson, PhD, Associate Director, Research and Development, National Institute for Health and Care Excellence (NICE), Manchester, UK

Yi Qian, PhD, Director, Amgen, Thousand Oaks, CA, USA


14:00 - 15:00
Room: Hall 1
P11: COST STUDIES

CS1

14:00 - 14:15

OBSERVED VERSUS ESTIMATED ACQUISITION COSTS ASSOCIATED WITH MEDICINES RECOMMENDED BY THE ALL WALES MEDICINES STRATEGY GROUP

Keeping S, Deslandes PN, Haines K, Routledge PA
All Wales Therapeutics and Toxicology Centre, Llandough, UK

CS2

14:15 - 14:30

COSTS OF CHEMOTHERAPY-INDUCED ADVERSE EVENTS IN HEAD AND NECK CANCER IN FRANCE

Lafuma A1, Cotte F2, Le Tourneau C3, Emery C4, Gaudin A2, Torreton E1, Gourmelen J5, Ouared C2, Bonastre J6
1Cemka-Eval, Bourg La Reine, France, 2Bristol-Myers Squibb, Rueil-Malmaison, France, 3Institut Curie, Paris, France, 4Cemka, Bourg La Reine, France, 5UMS 011 - Inserm - UVSQ, Villejuif, France, 6Gustave Roussy, Villejuif, France

CS3

14:30 - 14:45

COSTS OF ILLNESS PROGRESSION FOR DIFFERENT MULTIPLE SCLEROSIS PHENOTYPES: A POPULATION-BASED STUDY IN SWEDEN

Gyllensten H, Kavaliunas A, Hillert J, Alexanderson K, Tinghög P, Friberg E
Karolinska Institutet, Stockholm, Sweden

CS4

14:45 - 15:00

REAL LIFE COST OF TREATMENT AND FOLLOW-UP IN GLIOBLASTOMA MULTIFORME (GBM) PATIENTS TREATED AT THE ANTWERP UNIVERSITY HOSPITAL (UZA), BELGIUM

Van den Eede N1, De Paepe A1, Specenier P2, Strens D3
1University of Antwerp, Antwerpen, Belgium, 2Antwerp University Hospital, Edegem, Belgium, 3Realidad bvba, Grimbergen, Belgium

14:00 - 15:00
Room: Lomond Auditorium (Loch Suite)
P12: MODELING METHODS
Moderator: Talitha Feenstra, PhD
Assistant Professor, University Medical Center Groningen (UMCG), and National Institute for Public Health and the Environment (RIVM), Groningen, The Netherlands

MO1

14:00 - 14:15

CALIBRATION APPROACH IMPACT ON HEALTH AND COST-EFFECTIVENESS OUTCOMES IN A DECISION ANALYTIC FRAMEWORK

Moriña D, Díaz M
Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain

MO2

14:15 - 14:30

HOW IRELAND'S COLORECTAL SCREENING PROGRAMME COULD SAVE MORE LIVES, SAVE MONEY AND STAY WITHIN EXISTING COLONOSCOPY CAPACITY LIMITS: EVIDENCE FROM THE MISCAN MICROSIMULATION MODEL

McFerran E1, O'Mahony JF2
1QUEEN'S UNIVERSITY BELFAST, BELFAST, UK, 2Trinity College Dublin, Dublin, Ireland

MO3

14:30 - 14:45

MODELING COVARIATE-ADJUSTED SURVIVAL FOR ECONOMIC EVALUATIONS IN ONCOLOGY

Majer IM1, Castaigne J2, Palmer S3, DeCosta L4, Campioni M1
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Oncology, Cambridge, UK, 3University of York, Heslington, York, UK, 4Amgen Ltd., Uxbridge, UK

MO4

14:45 - 15:00

DIFFERENT METHODS FOR MODELLING SEVERE HYPOGLYCAEMIC EVENTS: IMPLICATIONS FOR EFFECTIVENESS AND COST-EFFECTIVENESS ANALYSES

Keeney E1, Dawoud D2, Dias S1
1University of Bristol, Bristol, UK, 2National Guideline Centre, Royal College of Physicians, London, UK
14:00 - 18:00
EDUCATIONAL FORUM
15:00 - 15:30
BREAK & EXHIBITS VIEWING (Hall 4)
Room: Hall 4
15:30 - 16:30
BREAKOUT SESSION

15:30 - 16:30
Room: Clyde Auditorium (Armadillo)

IP13: MCDA VALUATION AND ICERS – CAN THEY ALIGN FOR DECISION-MAKING PURPOSES? (INVITED ISSUE PANEL)

Moderator:

Louis P. Garrison, PhD, Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy University of Washington, Seattle, WA, USA

Panelists:

Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA

Maarten Ijzerman, PhD, MSc, Professor & Vice-Dean, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands

Nancy Devlin, PhD, Research Director, Office of Health Economics, London, UK


15:30 - 16:30
Room: Hall 3

IP14: PATIENT-CENTERED DECISION MAKING: HOW DO YOU GENERATE RELEVANT PATIENT-REPORTED OUTCOMES EVIDENCE FOR CHRONIC DISEASE MANAGEMENT AND MARKET-ACCESS DECISION MAKING?

Moderator:

Finn Børlum Kristensen, MD, PhD, Professor, Faculty of Health Sciences, University of Southern Denmark, Hilleroed, Denmark bio

Panelists:

Katharine Barnard, PhD CPsychol AFBPsS, Visiting Professor, Bournemouth University, Poole, UK

Simon O'Neill, REG.N., Director of Health Intelligence and Professional Liaison, Diabetes UK, London, UK

Francois Meyer, PhD, Advisor to the President, International Affairs, Haute Autorité de Santé (HAS), Saint-Denis, France


15:30 - 16:30
Room: Lomond Auditorium (Loch Suite)
W13: WHY IS YOUR OUTCOME DIFFERENT FROM MINE? DISCUSSING THE POTENTIAL IMPACT OF DESIGN CHOICES IN THE DEVELOPMENT OF DISCRETE EVENT SIMULATION MODELS
Discussion Leaders:

Elisabeth Fenwick, PhD, Senior Principal, Health Economics, Health Economics & Epidemiology, ICON plc, Abingdon, UK

Hendrik Koffijberg, PhD, Associate Professor Health Economics, Health Technology & Services Research, University of Twente, Enschede, The Netherlands

Beate Jahn, PhD, Senior Scientist, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

Koen Degeling, MSc, PhD Candidate Health Economics, Health Technology & Services Research, University of Twente, Enschede, The Netherlands


15:30 - 16:30
Room: Hall 2
W14: IMPACT OF PATIENT INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENTS: A CASE STUDY
Discussion Leaders:

Matthew May, BS, EUPATI Coordinator, EPF, 1000 Brussels, Belgium

Joan Jordan, EUPATI Fellow, Multiple Sclerosis Society of Ireland, Dublin, Ireland

Michael Barry, MB, FRCPI, PhD, Director, Trinity Centre for Health Sciences, St. James’s Hospital, National Centre for Pharmacoeconomics (NCPE), Dublin, Ireland

Orlaith Brennan, Director of Commercial Affairs, Irish Pharmaceutical Healthcare Association (IPHA), Dublin, Ireland


15:30 - 16:30
Room: Hall 1
P13: METHODOLOGICAL STUDIES IN CANCER
Moderator: Ursula Rochau, MSc
Assistant Professor, UMIT - University for Health Sciences, Medical Informatics and Technology, Tirol, Austria

CN5

15:30 - 15:45

PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Dimopoulos M1, Sonneveld P2, Nahi H3, Kumar S4, Hashim M5, Kulakova M5, Duran M5, Heeg B5, Lam A6, Dearden L6
1National and Kapodistrian University of Athens, Athens, Greece, 2Erasmus MC, Rotterdam, The Netherlands, 3Karolinska Institute, Stockholm, Sweden, 4Mayo Clinic, Rochester, MN, USA, 5Ingress Health, Rotterdam, The Netherlands, 6Janssen Global Services, LLC, Raritan, NJ, USA

CN6

15:45 - 16:00

CAN BAYESIAN METHODOLOGY PREDICT LONG-TERM EFFECTIVENESS RATHER THAN EFFICACY? AN APPLICATION WITH OVERALL SURVIVAL IN TWO ONCOLOGY INDICATIONS

Soikkeli F1, Hashim M1, Mueller S2, Groth A2, Wilke T3, Heeg B1
1Ingress Health, Rotterdam, The Netherlands, 2Ingress-Health HWM GmbH, Wismar, Germany, 3INGRESS-Health HWM GmbH, Wismar, Germany

CN7

16:00 - 16:15

ESTIMATING LONG-TERM SURVIVAL IN THE FACE OF IMMATURE DATA: A CASE STUDY OF NIVOLUMAB IN SECOND LINE RENAL CELL CARCINOMA

Klijn SL1, Torkilseng EB2, Tyas D3, Sowdani A3, Malcolm B3, Mudd A1, Johannesen KM4
1Pharmerit International, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Lysaker, Norway, 3Bristol-Myers Squibb, Uxbridge, UK, 4Bristol-Myers Squibb AB, Stockholm, Sweden

CN8

16:15 - 16:30

LENGTH OF TRIAL PERIOD AND FIT OF STANDARD SURVIVAL EXTRAPOLATION DISTRIBUTIONS FOR IPILIMUMAB IN MELANOMA

Ouwens MJ, Dalevi D
Astrazeneca, Molndal, Sweden

15:30 - 16:30
Room: Forth (Armadillo)
P14: SYSTEMIC DISORDERS/CONDITIONS STUDIES
Moderator: Bertalan Nemeth, MSc
Senior Health Economist, Syreon Research Institute, President-elect of the ISPOR Hungary Chapter, Budapest, Hungary

SY1

15:30 - 15:45

PSORIASIS DRUGS IN EUROPE - MARKET ACCESS DECISIONS IN COMPARISON BASED ON THE PRISM ACCESS DATABASE

Vollmer L1, de Paz B2, Droeschel D1, Walzer S1
1MArS- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 2PRIORITIS Market Access, Paris, France

SY2

15:30 - 15:45

WITHDRAWN

SY3

15:45 - 16:00

HOW WILL PAYERS MANAGE THE COST OF NEW, ADVANCED BIOLOGIC AND ONCOLOGIC AGENTS AS THERAPY AREAS BECOME CROWDED WITH DRUGS WITH SIMILAR MECHANISMS OF ACTION?

Paglia R, Del Carlo A, Schwartz J, Carter EA
Consulting at McCann Health, New York, NY, USA

SY4

16:00 - 16:15

DO EU5 COUNTRIES WITH FAVOURABLE HEALTHCARE EXPENDITURE AND REIMBURSEMENT INDICATORS HAVE BETTER PATIENT-REPORTED ACCESS TO TREATMENTS FOR RARE DISEASES?

Allen G1, Hall A1, Hanman K2, Le Fevre R1, Griffiths A1
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Consulting Ltd, London, UK
15:30 - 19:15
RESEARCH POSTER PRESENTATIONS - SESSION IV
16:30 - 17:45
ISPOR EUROPE CHAPTERS PRESIDENTS AND EUPATI MEETING
Room: Dochart (Loch Suite)
EUPATI, the European Patients’ Academy, provides scientifically reliable and comprehensive information to patients and the general public on the medicines research and development process to enable their involvement. EUPATI was established in 2012 as a project funded by the Innovative Medicines Initiative and set out to educate patients across Europe via various platforms. EUPATI has since become a programme under the auspice of the European Patients’ Forum (EPF), maintaining the public-private partnership spirit. The key assets of EUPATI – an Expert Training Course, a Toolbox and a Website are continuing to educate and empower patients for a more active role as partner in all aspects of medicines research and development. The work of EUPATI includes strong collaboration with the EUPATI National Platforms (national education/ empowerment teams in 18 countries and growing) as well as other initiatives in the field of patient engagement. This session looks at a brief introduction to EUPATI and the EUPATI National Platforms and how the EUPATI National Platforms and ISPOR Chapters can explore synergies and opportunities in working together in the future.
16:45 - 17:45
BREAKOUT SESSION

16:45 - 17:45
Room: Hall 1

IP15: A MODEST PROPOSAL: CAN WE EASE THE BURDEN OF MYRIAD MEASURES WITH A MINIMUM DATA SET THAT ACTUALLY MATTERS TO PATIENTS?

Moderator:

Roman Casciano, MS, Executive Vice President & General Manager, Consulting & Analytics & Global Head, Value & Access, ANALYTICA LASER, New York, NY, USA

Panelists:

Sheela Upadhyaya, MSc, Associate Director - Highly Specialised Technologies, NICE - National Institute for Health and Care Excellence, London, UK

Charles D. Petrie, PhD, Vice President, Outcomes and Evidence, Global Health & Value, Pfizer, Inc., Groton, CT, USA

Bettina Ryll, MD, PhD, Founder, and Researcher, Melanoma Patient Network Europe, and Uppsala University (Department EBC), Uppsala, Sweden


16:45 - 17:45
Room: Hall 3

IP16: MANAGED ENTRY SCHEMES FOR MEDICAL DEVICES: GREAT OPPORTUNITY OR MAJOR CHALLENGE?

Moderator:

Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Panelists:

Aleksandra Torbica, PhD, Professor, Bocconi University, Milano, Italy

Richard Charter, MSc, Head of Market Access & Pricing, Becton Dickinson, Allschwil, Switzerland

Denis Gizzi, BSc, Managing Director, NHS Oldham Clinical Commissioning Group, Sheffield Hallam University, Oldham, UK

Brian Mangan, FCIPS MSc, Deputy Director, NHS NW Procurement Development, Wigan, UK


16:45 - 17:45
Room: Clyde Auditorium (Armadillo)
W15: TIME FOR A CHANGE? ALTERNATIVE APPROACHES TO MODELLING IN CANCER VALUE ASSESSMENTS
Discussion Leaders:

Meindert Boysen, PharmD, MSc, Professor, Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, and Programme Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), London, UK

Robert Hettle, MMath, Vice President (Technical) of Health Economic modelling, HERON Commercialization, PAREXEL International, London, UK

Beth Woods, MSc, Senior Research Fellow, Team for Economic Evaluation and Health Technology Assessment (TEEHTA), Centre for Health Economics, University of York, Heslington, York, UK

Marta Soares, MSc, Senior Research Fellow, Team for Economic Evaluation and Health Technology Assessment (TEEHTA), Centre for Health Economics, University of York, Heslington, York, UK


16:45 - 17:45
Room: Lomond Auditorium (Loch Suite)
W16: UNDERSTANDING THE VALUE AND FEASIBILITY OF ENGAGING PATIENTS IN THE DESIGN OF CLINICAL TRIALS AND CLINICAL OUTCOME ASSESSMENT MEASUREMENT STRATEGIES: INSIGHTS FROM EXPERIENCES IN ONCOLOGY AND GOUT
Discussion Leaders:

Bryan Bennett, PhD, Director, Patient-Centered Outcomes, Adelphi Values Ltd, Bollington, Cheshire, UK

Sophi Tatlock, MA, Associate Director, Patient-Centered Outcomes, Adelphi Values Ltd, Bollington, Cheshire, UK

Stephanie Manson, PhD, Senior Director, HEOR Excellence, Novartis, East Hanover, NJ, USA

Katja Rudell, PhD, Teaching Fellow, Queen Mary University of London, London, UK


16:45 - 17:45
Room: Hall 2
P15: HEALTH TECHNOLOGY ASSESSMENT STUDIES
Moderator: Hendrik Koffijberg, MSc, PhD
Associate Professor, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands

HT5

16:45 - 17:00

“APPRAISING THE APPRAISERS”: DO NATIONAL HEALTH TECHNOLOGY ASSESSMENT AGENCIES (NICE, GBA/IQWIG) FOLLOW THEIR OFFICIAL EVALUATION CRITERIA?

Schaefer R1, Schwarz O2, Schlander M3
1German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany, 2University of Heilbronn, Wiesbaden, Germany, 3University of Heidelberg, Heidelberg, Germany

HT6

17:00 - 17:15

ASSESSMENT OF MEDICINES FOR VERY RARE CONDITIONS: REVIEW OF A NEW APPROACH WITHIN THE SCOTTISH MEDICINES CONSORTIUM

Jones J, Brown A, Lee A, MacDonald A
Healthcare Improvement Scotland, Glasgow, UK

HT7

17:15 - 17:30

WHAT DO THE SINGLE TECHNOLOGY APPRAISALS OF THE PAST TELL US ABOUT FAST-TRACKING THE MOST COST-EFFECTIVE NEW TECHNOLOGIES IN THE FUTURE?

Boland A1, Houten R1, Carroll C2, Kaltenthauer E2, Dickson R1
1University of Liverpool, Liverpool, UK, 2University of Sheffield, Sheffield, UK

HT8

17:30 - 17:45

THE USE OF PUBLISHED REAL-WORLD EVIDENCE IN HTA: AN ANALYSIS OF THE EVIDENCE BASE OF COMPANY SUBMISSIONS IN 2016 NICE APPRAISALS

Van Lier H, de Boeck M, Edwards V, Hanekamp E, Hartog TE, Richmond G, van den Broek R
Excerpta Medica, Amsterdam, The Netherlands

16:45 - 17:45
Room: Forth (Armadillo)
P16: INFECTIOUS DISEASE STUDIES
Moderator: JL (Hans) Severens, PhD
Professor of Evaluation in Health Care, Erasmus School of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands

IN1

16:45 - 17:00

ESTIMATING THE PUBLIC ECONOMIC IMPACT OF DIFFERENT HEPATITIS C HEALTHCARE POLICIES IN THE NETHERLANDS

Connolly M1, Kotsopoulos N2
1University of Groningen, Groningen, The Netherlands, 2Global Market Access Solutions, Saint-Prex, Switzerland

IN2

17:00 - 17:15

COST-EFFECTIVENESS AND MODELING APPROACHES OF DIRECT-ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC LITERATURE REVIEW

Szilberhorn L1, Ágh T2, Fasseeh AN1, Kaló Z1
1Eötvös Loránd University (ELTE), Budapest, Hungary, 2Syreon Research Institute, Budapest, Hungary

IN3

17:15 - 17:30

DIFFERENCES IN VACCINE PRICING BETWEEN HIGH-INCOME AND LOW-INCOME MARKETS

Fadeyi I, McLean T, Tavella F, Heron L
Adelphi Values Ltd, Bollington, UK

IN4

17:30 - 17:45

COST-EFFECTIVENESS OF ADDITIONAL VACCINATION OF BOYS AGAINST HPV IN GERMANY

Damm O1, Horn J2, Ultsch B3, Scholz S1, Mikolajczyk R2, Wiese-Posselt M3, Harder T3, Wichmann O3, Greiner W1
1School of Public Health, Bielefeld University, Bielefeld, Germany, 2Helmholtz Centre for Infection Research, Brunswick, Germany, 3Immunisation Unit, Robert Koch Institute, Berlin, Germany
17:45 - 19:15
EXHIBITORS' WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV (Hall 4)
Room: Hall 4
18:00 - 19:00
BREAKOUT SESSION

18:00 - 19:00
Room: Clyde Auditorium (Armadillo)
F7: HEALTH STATE UTILITY (HSU) IDENTIFICATION AND USE IN COST-EFFECTIVENESS IN DECISION MODELLING - AN ISPOR TASK FORCE
Moderator:

John Brazier, PhD, MSc, Professor of Health Economics and Dean, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Speakers:

Helene Chevrou-Severac, PhD, HEOR Director, Medical Affairs, Celgene International, Boudry, Switzerland

Roberta Ara, MSc, Senior Research Fellow, School of Health and Related Research, The University of Sheffield, Sheffield, UK

Andrew Lloyd, PhD, Director, Acaster Lloyd Consulting Ltd., Oxford, UK


18:00 - 19:00
Room: Hall 3
F8: INNOVATION AND MARKET ACCESS IN ASIA-PACIFIC: WHAT EVIDENCE AND PROCESSES ARE APPROPRIATE FOR REIMBURSEMENT? CHINA, JAPAN, SOUTH KOREA, TAIWAN AND AUSTRALIA COMPARED.
Moderator:

Mendel Grobler, B.Pharm, MBA, Director and Head of Health Policy – JAPAC and Emerging Markets, Amgen Inc., North Ryde, NSW, Australia

Speakers:

Shanlian Hu, MS, MD, Senior Consultant, Shanghai Health Development Research Center, Shanghai, China

Bruce Crawford, MA, MPH, Vice President, Real World Evidence & Insights, InVentiv Health Japan G.K., Tokyo, Japan

Sukyeong Kim, PhD, RPh, MPH, Director, Coordinating Center for National Health Clinical Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)

Chee-Jen Chang, PhD, MS, President, Taiwan Society for Pharmacoeconomics and Outcome Research, Director, Clinical Informatics and Medical Statistics Research Center, and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Tao Yuan, Taiwan


18:00 - 19:00
Room: Hall 1
F9: LATE STAGE ONCOLOGY MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Moderator:

Vladimir Zah, PhD, Health Economics Consultant and CEO, ZRx Outcomes Research Inc., Belgrade, Serbia

Speakers:

Oresta Piniazhko, PhD, President, ISPOR Ukraine Chapter, Assistant Professor, Member of Expert Committee of MoH, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Niki Popper, Dipl.Ing., Dr., President, ISPOR Austria Chapter, Professor, University of Technology Vienna, Vienna, Austria

Aleksandra Zawodnik, MSc Pharm, PhD Candidate, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

Bertalan Nemeth, MSc, Senior Pharmacoeconomist, Syreon Research Institute, Budapest, Hungary


18:00 - 19:00
Room: Forth (Armadillo)
F10: THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE
Moderator:

Maria Kamusheva, PhD, Assistant Professor, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

Speakers:

Josip Culig, MD, PhD, Professor, Pharmacology & Clinical Pharmacology & Head, Pharmacoepidemiology Department, Andrija Stampar Institute of Public Health, Zagreb, Croatia

Konstantin Tachkov, PhD(c), PhD student, Medical University of Sofia, Sofia, Bulgaria

Tamas Agh, MD, MSC, PhD, Principal Researcher, Syreon Research Institute, Hungary, Hungary

Mary Geitona, MD, Professor, Health Economics, Department of Social and Educational Policy, University of Peloponnese, Korinthos, Greece


18:00 - 19:00
Room: Lomond Auditorium (Loch Suite)
F11: THE NEW PARADIGM OF CANCER TREATMENTS: A CHALLENGE FOR THE HEALTH SYSTEMS?
Moderator:

Carme Pinyol, MD, PhD, MSc, President, ISPOR Spain Chapter, Head of Pricing and Market Access Southern Europe, Pierre Fabre, Barcelona, Spain

Speakers:

César Hernández, PhD, Head of the Department of Drugs of Human Use, Spanish Agency of Medicines and Health Products, Barcelona, Spain

Jorge Mestre-Ferrandiz, PhD, Consultant, Expert in Pharmacoeconomics, OHE Collaborator, Madrid, Spain


18:00 - 19:00
Room: Hall 2
F12: IMPLEMENTING ADAPTIVE PATHWAYS IN EUROPE: A CENTRAL AND EASTERN EUROPE (CEE) FOCUS
Moderator:

André Broekmans, MD, PhD, Director Escher, Lygature and Coordinator, ADAPT SMART, Utrecht, The Netherlands

Speakers:

Zoltan Kalo, PhD, Professor of Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary

Tomas Tesar, PharmD, PhD, MBA, MPH, MSc, Member of the Reimbursement Committee, Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovakia

Dominik Tomek, PharmD, MPH, PhD, President, ISPOR Slovakia Chapter, and Senior Researcher, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic

18:15 - 19:15
POSTER AUTHOR DISCUSSION HOUR - SESSION IV (Hall 4)
Room: Hall 4
19:30 - 23:30
ISPOR SOCIAL EVENT

Join us for whisky tasting, dinner, and traditional dancing and music.  The event takes place at Merchant Square, once part of the old Glasgow Fruit Market, in the heart of Glasgow.  Guests will enjoy Scottish appetizers, whisky tasting, and have a choice of dinner options at the 5 restaurants within Merchant Square. A demonstration of Ceilidh dancing will be given and all will have the opportunity to participate in this easy-to-learn traditional dancing.  Separate registration is required. The price is 90 Euros and includes transportation from the SEC to Merchant Square and back to the SEC, buffet dinner, 2 drinks, and entertainment.

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.